晶云藥物是一家技術(shù)驅(qū)動(dòng)的，專(zhuān)注于藥物晶型研究、制劑開(kāi)發(fā)和生產(chǎn)以及臨床供應(yīng)的CRO/CDMO，致力于為小分子新藥客戶提供量身定制的“首次正確”的晶型和制劑。

晶云藥物成立于2010年，在中國(guó)蘇州、美國(guó)新澤西和加拿大多倫多均設(shè)有研發(fā)和生產(chǎn)中心，擁有一支超過(guò)250人的專(zhuān)業(yè)團(tuán)隊(duì)，已與全球1000多家制藥企業(yè)展開(kāi)合作，為2000多個(gè)新藥化合物提供專(zhuān)業(yè)技術(shù)方案。在中國(guó)排名前20的創(chuàng)新藥企業(yè)中，有19家選擇了晶云藥物的服務(wù)；在全球排名前10的制藥企業(yè)中，有8家是晶云藥物的客戶。

Crystal Pharmatech, established in 2010, is a global company with approximately 250 employees and three R&D centers located in Suzhou (China), New Jersey (USA), and Toronto (Canada). Our key differentiator is our integrated and specialized services, including API solid-state research, crystallization, preformulation, formulation development, and manufacturing.

With an average of 20 years of experience, our scientific leadership team has successfully delivered over 100 early phase and 19 commercialized products for global pharmaceutical companies. We have served over 1,000 clients, supporting more than 2,000 new chemical entities.